Continue this baseline protocol for four to six weeks
[1] [7] Other notable effects include injection site reactions beyond pain (erythema, pruritus, induration in 13% of patients), increased heart rate (particularly with liraglutide), gallbladder disease (including gallstones and cholecystitis), and potential dehydration-related acute kidney injury
TLDR: Peptide syringe sizes describe barrel capacity, such as 0.3 mL, 0.5 mL, or 1 mL
Compared to other anti-obesity medications (e.g., dulaglutide and semaglutide) administered over the same duration, tirzepatide demonstrated a superior reduction in body fat compartments, including total fat mass, VAT, and waist circumference [63]